In addition, SH2D1A expression in tumor purity was found to be significantly correlated with the expression of the immune cell markers VSIG4, CD3E, CD2, TBX21, KIR2DS4, CD3D, CD79A, PDCD1, STAT5B, CTLA4, CCR7, HLA-DPA1, CD163, IFNG, CD86, KIR3DL1, HLA-DRA, LAG3, ITGAX, GZMB, CCR8, STAT4, IL13, HAVCR2, CD19, CD1C, CD8A, TNF, MS4A4A, STAT1, KIR2DL4, IL10, HLA-DQB1, FOXP3, STAT5A, CD8B, KIR3DL2, CD68, CCL2, TGFB1, KIR2DL3, ITGAM, HLA-DPB1, PTGS2, IL21, NRP1, CSF1R, IL17A, STAT6, GATA3, KIR3DL3, STAT3, IRF5, and BCL6 (Table 3). This evidence concerns the gene CCL2 and neoplasm.